The Discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors

被引：23

作者：

Buckmelter, Alex J. ^{[1
]}

Ren, Li ^{[1
]}

Laird, Ellen R. ^{[1
]}

Rast, Bryson ^{[1
]}

Miknis, Greg ^{[1
]}

Wenglowsky, Steve ^{[1
]}

Schlachter, Stephen ^{[1
]}

Welch, Mike ^{[1
]}

Tarlton, Eugene ^{[1
]}

Grina, Jonas ^{[1
]}

Lyssikatos, Joseph ^{[2
]}

Brandhuber, Barbara J. ^{[1
]}

Morales, Tony ^{[1
]}

Randolph, Nikole ^{[1
]}

Vigers, Guy ^{[1
]}

Martinson, Matthew ^{[1
]}

Callejo, Michele ^{[1
]}

机构：

[1] Array BioPharma, Boulder, CO 80301 USA

[2] Genentech Inc, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 04期

关键词：

B-Raf; Kinase; Cancer therapy; DESIGN; KINASE; MUTATIONS; PYRAZINES; ENERGY;

D O I：

10.1016/j.bmcl.2010.12.039

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Virtual and high-throughput screening identified imidazo[1,2-a]pyrazines as inhibitors of B-Raf. We describe the rationale, SAR, and evolution of the initial hits to a series of furo[2,3-c]pyridine indanone oximes as highly potent and selective inhibitors of B-Raf. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1248 / 1252

页数：5

共 31 条

[1] Raf: A strategic target for therapeutic development against cancer
Beeram, M
Patnaik, A
Rowinsky, EK
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6771 - 6790
[2] STUDY OF SRN1 REACTIONS .10. ACTION OF SULFANIONS ON FUNCTIONALIZED ARYL HALIDES - DIRECT SYNTHESIS OF BENZOTHIOPHENES AND THIENOPYRIDINES
BEUGELMANS, R
BOISCHOUSSY, M
BOUDET, B
[J]. TETRAHEDRON, 1983, 39 (24) : 4153 - 4161
[3] Bienaymé H, 1998, ANGEW CHEM INT EDIT, V37, P2234, DOI 10.1002/(SICI)1521-3773(19980904)37:16<2234::AID-ANIE2234>3.0.CO
[4] 2-R
[5] Parallel synthesis of 3-aminoimidazo[1,2-a]pyridines and pyrazines by a new three-component condensation
Blackburn, C
Guan, B
Fleming, P
Shiosaki, K
Tsai, S
[J]. TETRAHEDRON LETTERS, 1998, 39 (22) : 3635 - 3638
[6] Chan AWE, 1996, BIOORGAN MED CHEM, V4, P1673
[7] Biotransformation reactions of five-membered aromatic heterocyclic rings
Dalvie, DK
Kalgutkar, AS
Khojasteh-Bakht, SC
Obach, RS
O'Donnell, JP
[J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (03) : 269 - 299
[8] Mutations of the BRAF gene in human cancer
Davies, H
Bignell, GR
Cox, C
Stephens, P
Edkins, S
Clegg, S
Teague, J
Woffendin, H
Garnett, MJ
Bottomley, W
Davis, N
Dicks, N
Ewing, R
Floyd, Y
Gray, K
Hall, S
Hawes, R
Hughes, J
Kosmidou, V
Menzies, A
Mould, C
Parker, A
Stevens, C
Watt, S
Hooper, S
Wilson, R
Jayatilake, H
Gusterson, BA
Cooper, C
Shipley, J
Hargrave, D
Pritchard-Jones, K
Maitland, N
Chenevix-Trench, G
Riggins, GJ
Bigner, DD
Palmieri, G
Cossu, A
Flanagan, A
Nicholson, A
Ho, JWC
Leung, SY
Yuen, ST
Weber, BL
Siegler, HF
Darrow, TL
Paterson, H
Marais, R
Marshall, CJ
Wooster, R
[J]. NATURE, 2002, 417 (6892) : 949 - 954
[9] Oncogenic B-Raf mutations: Crystal clear at last
Dhillon, AS
Kolch, W
[J]. CANCER CELL, 2004, 5 (04) : 303 - 304
[10] Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T.
Ahmad, T.
Flaherty, K. T.
Gore, M.
Kaye, S.
Marais, R.
Gibbens, I.
Hackett, S.
James, M.
Schuchter, L. M.
Nathanson, K. L.
Xia, C.
Simantov, R.
Schwartz, B.
Poulin-Costello, M.
O'Dwyer, P. J.
Ratain, M. J.
[J]. BRITISH JOURNAL OF CANCER, 2006, 95 (05) : 581 - 586

← 1 2 3 4 →